Balyasny Asset Management
GLMD icon

Balyasny Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Balyasny Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-703
Closed -$1.51M – 1804
2018
Q2 		$1.51M Buy
+703
New +$1.02M 0.01% 1025

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's GLMD Position: Q3 2018 in Review

Balyasny Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q3 2018, closing a stake of 703 shares — an estimated $1.51M sold.

Balyasny Asset Management first reported a position in GLMD in Q2 2018 and held it in 1 quarter. The position peaked at $1.51M in Q2 2018. 38 funds tracked by Wall St. Rank hold GLMD as of Q3 2018.

  • Balyasny Asset Management reported no remaining Galmed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 703 Galmed Pharmaceuticals shares in Q3 2018, an estimated $1.51M.
  • Balyasny Asset Management first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Balyasny Asset Management's Galmed Pharmaceuticals position peaked at $1.51M in Q2 2018.
  • 38 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.